OptiNose (OPTN) Prices 5.5M Public Offering of Common Stock at $9.75/Share

Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $9.75 per share, before underwriting discounts. The offering consists of 4,250,000 shares being sold by Optinose and 1,250,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $39.0 million to Optinose and approximately $11.5 million to the selling stockholders, after deducting underwriting discounts and before offering expenses. In addition, Optinose and the selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to an additional 825,000 shares at the public offering price, less the underwriting discount. The offering is expected to close on or about November 25, 2019, subject to the satisfaction of customary closing conditions.

Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes. Optinose will not receive any proceeds from the sale of shares by the selling stockholders.

Jefferies, Cowen and Piper Jaffray are acting as the joint lead book-running managers for the offering. BMO Capital Markets is acting as book-running manager for the offering.

You May Also Be Interested In

• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• Singularity Future Technology closes $5M registered direct offering
• Baiya International Group (BIYA) files $200M mixed shelf